(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 2.44% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Viatris's revenue in 2026 is $14,737,300,000.On average, 12 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,303,521,366,160, with the lowest VTRS revenue forecast at $16,491,467,625,312, and the highest VTRS revenue forecast at $18,021,390,656,160. On average, 12 Wall Street analysts forecast VTRS's revenue for 2027 to be $17,643,504,261,904, with the lowest VTRS revenue forecast at $16,693,619,617,376, and the highest VTRS revenue forecast at $18,501,501,637,312.
In 2028, VTRS is forecast to generate $18,253,406,010,688 in revenue, with the lowest revenue forecast at $17,193,256,643,216 and the highest revenue forecast at $19,001,138,663,152.